Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer

被引：0
作者：
Blossom Mak
Hui-Ming Lin
Edmond M. Kwan
Heidi Fettke
Ben Tran
Ian D. Davis
Kate Mahon
Martin R. Stockler
Karen Briscoe
Gavin Marx
Alison Zhang
Megan Crumbaker
Winston Tan
Kevin Huynh
Thomas G. Meikle
Natalie A. Mellett
Andrew J. Hoy
Pan Du
Jianjun Yu
Shidong Jia
Anthony M. Joshua
David J. Waugh
Lisa M. Butler
Manish Kohli
Peter J. Meikle
Arun A. Azad
Lisa G. Horvath
机构：
[1] Chris O’Brien Lifehouse,Sir Peter MacCallum Department of Oncology
[2] Garvan Institute of Medical Research,Eastern Health Clinical School
[3] University of Sydney,School of Medical Sciences, Charles Perkins Centre, Faculty of Medicine and Health
[4] St Vincent’s Clinical School,Adelaide Medical School and Freemason’s Foundation Centre for Men’s Health
[5] UNSW,Department of Medicine, School of Clinical Sciences
[6] Monash Health,undefined
[7] Peter MacCallum Cancer Centre,undefined
[8] University of Melbourne,undefined
[9] Monash University,undefined
[10] Eastern Health,undefined
[11] Royal Prince Alfred Hospital,undefined
[12] Concord Repatriation General Hospital,undefined
[13] Mid North Coast Cancer Institute,undefined
[14] Sydney Adventist Hospital,undefined
[15] The Kinghorn Cancer Centre,undefined
[16] St Vincent’s Hospital,undefined
[17] Mayo Clinic,undefined
[18] Baker Heart and Diabetes Institute,undefined
[19] University of Sydney,undefined
[20] Predicine,undefined
[21] Inc.,undefined
[22] Queensland University of Technology,undefined
[23] University of Adelaide,undefined
[24] South Australian Health and Medical Research Institute,undefined
[25] Huntsman Cancer Institute,undefined
[26] Monash University,undefined
来源：
BMC Medicine | / 20卷
关键词：
Androgen receptor; Biomarker; Castration-resistant prostate cancer; Genomics; Lipid; PI3K; RB1; TP53;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 204 条
  • [1] Sung H(2021)Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries CA Cancer J Clin. 71 209-249
  • [2] Ferlay J(2018)Metastatic Prostate Cancer N Engl J Med. 378 645-657
  • [3] Siegel RL(2016)Obesity and cancer mechanisms: tumor microenvironment and inflammation J Clin Oncol. 34 4270-4276
  • [4] Laversanne M(2015)Integrative clinical genomics of advanced prostate cancer Cell. 161 1215-1228
  • [5] Soerjomataram I(2019)Towards precision oncology in advanced prostate cancer Nat Rev Urol. 16 645-654
  • [6] Jemal A(2019)Genomic correlates of clinical outcome in advanced prostate cancer Proc Natl Acad Sci U S A. 116 11428-11436
  • [7] Sartor O(2018)Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer Cancer Discov. 8 444-457
  • [8] de Bono JS(2013)Obesity and prostate cancer: weighing the evidence Eur Urol. 63 800-809
  • [9] Iyengar NM(2011)Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis Cancer Prev Res (Phila). 4 486-501
  • [10] Gucalp A(2011)Presence of the metabolic syndrome is associated with shorter time to castration-resistant prostate cancer Ann Oncol. 22 801-807
12345678910